North American urothelial carcinoma market is estimated to grow significantly at a CAGR of around 9.4% during the forecast period. Major factors that are augmenting the growth of the North American urothelial carcinoma market include increasing healthcare expenditure, raising awareness of cancer among the population, and surging aging population base coupled with the significant prevalence of urothelial carcinoma across the region. Moreover, the changing lifestyle, such as the consumption of alcohol and tobacco, is a major factor that increases the possibilities of diseases such as cancer. Thereby, resulting in driving the market for urothelial carcinoma across the region.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-american-urothelial-carcinoma-market
North American urothelial carcinoma market is segmented on the basis of countries in the region, namely the US and Canada. The US urothelial carcinoma market contributed the major share in the North America urothelial carcinoma market in 2019. American Cancer Society has provided bladder cancer statistics for 2019 in the US. The society estimates that around 17,670 mortalities will be due to bladder cancer in 2019. Moreover, around 73% of all these mortalities will be in men and the rest will be in women. It has been observed that the rates of new bladder cancers and mortalities caused by them are dropping slightly in women in recent years. Still, North America contributes a significant share in the global urothelial carcinoma market.
North American urothelial carcinoma market is segmented into diagnosis and treatment. Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. Transitional cell urothelial carcinoma is the most common type of urothelial carcinoma. As per the Canadian Cancer Society, it makes up over 90% of all urothelial carcinomas.
The companies which are contributing to the growth of the North American urothelial carcinoma market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc., and Spectrum Pharmaceuticals, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
North American Urothelial Carcinoma Market- Segmentation
By Diagnosis
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (IVP)
- Others (Biomarkers)
By Treatment
- Surgery
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Others (Targeted Therapy)
A full report of North American Urothelial Carcinoma Market is available at: https://www.omrglobal.com/industry-reports/north-american-urothelial-carcinoma-market
North American Urothelial Carcinoma Market– Segment by Region
- United States
- Canada
